danafarberbostonchildrens.org
Jun 23, 2025, 11:22
Riten Kumar Shared New ISTH Data: 3-Month Apixaban Course Shows Better Safety Profile Than Rivaroxaban in Acute VTE
Riten Kumar, Associate Professor of Pediatrics at Harvard, posted on X:
“Late breaking abstract at isth – 3 months of apixaban is safer than rivaroxaban for management of acute VTE!!!”
Be updated with Hemostasis Today.
-
Aug 9, 2026, 18:10James P. Crowley: How Turmeric and Green Tea May Affect Blood Sugar and Blood Pressure
-
Aug 9, 2026, 18:08Ahmed Alotaibi: How Many Lives Could Nationwide Prehospital Blood Access Potentially Save?
-
Aug 9, 2026, 18:06Are We Measuring What Matters Most in ITP? – ITP Australia and New Zealand
-
Aug 9, 2026, 18:03Mohamed Allaf: Aspirin and Clopidogrel Show Comparable Long-Term Survival After TAVI
-
Aug 9, 2026, 18:00Sangeeta Pathak: Delivering a Talk on Sustainable Blood Systems and Haemovigilance
-
Aug 9, 2026, 15:33Tareq Abadl: Kell System and Anti-K Alloimmunization
-
Aug 9, 2026, 15:16Antonella Cordoba: Emicizumab and the Evolving Landscape of Hemophilia A
-
Aug 9, 2026, 14:53Daniel Pereira Monteiro: Understanding Isoelectric Focusing in Hemoglobin Testing
-
Aug 9, 2026, 14:23Retheesh Das։ Edema Is a Sign, Not a Diagnosis